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        Notch signaling is initiated when a Notch li-
gand interacts with a Notch transmembrane 
receptor expressed on an adjacent cell (  1  ). This 
interaction triggers a series of proteolytic diges-
tions that releases the Notch intracellular do-
main (NotchIC), allowing it to translocate into 
the nucleus. Within the nucleus, NotchIC binds 
to the transcriptional repressor CSL, resulting in 
derepression and coactivation of Notch down-
stream target genes and thereby regulating vari-
ous cellular processes, including diff  erentiation, 
proliferation, and apoptosis. Interestingly, in the 
development of cancer, Notch may act as either 
an oncogene or a tumor suppressor gene depend-
ing on the tumor type (  2  ). 
  Mammary-specifi  c overexpression of constitu-
tively active Notch1IC, Notch3IC, or Notch4IC 
in mice leads to the formation of aggressive, meta-
static breast tumors (  3, 4  ). Recent studies have 
also highlighted a potential role for Notch sig-
naling in human breast cancer development. 
Expression of all four Notch receptors has been 
reported in human breast tumors at varying 
frequencies (  5  ). Poorly differentiated breast 
tumors are associated with elevated Notch1 pro-
tein levels and reduced patient survival (  6  ). 
Interestingly, an association between increased 
mRNA expression of the Notch ligand Jagged1 
and reduced survival in patients with breast 
cancer has recently been reported, with high-
level coexpression of Jagged1 and Notch1 
mRNA defi  ning a subset of patients with very 
poor outcome (  7  ). Notch has also been re-
ported to be activated downstream of Ras and 
Wnt in the promotion of mammary tumors 
through the induction of Notch ligands and/or 
receptors (  8, 9  ). Notch signaling may contrib-
ute to tumorigenesis by promoting mammary 
epithelial cell growth or inhibiting apoptosis 
(  10, 11  ). However, much remains to be learned 
about the molecular mechanisms of Notch-
mediated oncogenesis. 
  Numerous reports have indicated a role for 
epithelial-to-mesenchymal transition (EMT) in 
promoting the invasion and dissemination of 
malignant cells, particularly in breast cancer (  12  ). 
Recent studies have suggested that Notch sig-
naling induces a specialized type of EMT dur-
ing normal heart development and that Notch 
CORRESPONDENCE  
  Aly Karsan:  
 akarsan@bccrc.ca
  Abbreviations used: 5AZA, 
5-azacytidine; cDNA, comple-
mentary DNA; CpG, 
cytosine-phosphate-guanine; 
EMT, epithelial-to-mesenchy-
mal transition; HA, hemag-
glutinin; HDAC, histone 
deacetylase; MSP, methylation-
specifi  c PCR; NaBu, sodium 
butyrate; NotchIC, Notch in-
tracellular domain; qPCR, 
quantitative RT-PCR; shRNA, 
short hairpin RNA; siRNA, 
small interfering RNA; TSA, 
trichostatin A; YFP, yellow 
fl  uorescent protein. 
  K.G. Leong, K. Niessen, and I. Kulic contributed equally to 
this work. 
      The online version of this article contains supplemental material.   
  Jagged1-mediated Notch activation induces 
epithelial-to-mesenchymal transition through 
Slug-induced repression of E-cadherin 
  Kevin G. Leong,  1,2,4   Kyle Niessen,  1,2,4   Iva Kulic,  1,2,4   Afshin Raouf,  3   
Connie Eaves,  3,4,5,6   Ingrid Pollet,  1,2,5   and Aly Karsan  1,2,4,5   
  1  Department of Medical Biophysics,   2  Department of Pathology and Laboratory Medicine, and   3  Terry Fox Laboratory, 
British Columbia Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada 
  4  Experimental Medicine Program,   5  Department of Pathology and Laboratory Medicine, and   6  Department of Medical Genetics, 
University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada   
  Aberrant expression of Jagged1 and Notch1 are associated with poor outcome in breast 
cancer. However, the reason that Jagged1 and/or Notch overexpression portends a poor 
prognosis is unknown. We identify Slug, a transcriptional repressor, as a novel Notch target 
and show that elevated levels of Slug correlate with increased expression of Jagged1 in 
various human cancers. Slug was essential for Notch-mediated repression of E-cadherin, 
which resulted in     -catenin activation and resistance to anoikis. Inhibition of ligand-
induced Notch signaling in xenografted Slug-positive/E-cadherin  –  negative breast tumors 
promoted apoptosis and inhibited tumor growth and metastasis. This response was associ-
ated with down-regulated Slug expression, reexpression of E-cadherin, and suppression of 
active     -catenin. Our fi  ndings suggest that ligand-induced Notch activation, through the 
induction of Slug, promotes tumor growth and metastasis characterized by epithelial-to-
mesenchymal transition and inhibition of anoikis. 2936 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
positive human breast cancers. Jagged1-mediated activation 
of Notch in breast epithelial cells induces EMT through 
induction of Slug and subsequent repression of the cell  –  cell 
adhesion protein E-cadherin. Because Slug can be induced 
by factors other than Notch, we identify Notch downstream 
target genes of the HEY family as potential markers of pri-
mary human breast tumors that have activated the Jagged1  – 
Notch  –  Slug signaling axis. In Slug-positive/E-cadherin –  negative 
up-regulates Snail in endothelial cells to promote mesenchy-
mal transformation (  13, 14  ). However, there is no direct or 
even correlative in vivo data that Notch regulates EMT in 
epithelial cancers. 
  In this paper, we identify Slug, a zinc-fi  nger transcrip-
tional repressor functionally linked to human breast cancer 
progression and metastasis (  15  ), to be a direct downstream target 
gene of Notch that is up-regulated in Jagged1- and Notch1-
  Figure 1.     Notch activation inhibits E-cadherin expression in human breast epithelial cells through the induction of Slug. (A) Immunofl  uorescent 
staining for E-cadherin (red), YFP (green), and DAPI (blue) in primary human breast epithelial cells transduced with MIY, MIYNotch1IC, or MIYNotch4IC. 
Bar, 50     m. (B) qPCR for expression of E-cadherin, Slug, Snail, and Twist1 in MCF-10A cells transduced with MIY or MIYNotch1IC. Data are expressed as the 
relative gene expression level, with MIY control as the comparator, and are from three independent experiments (mean + SEM). *, P   ≤   0.05. (C) Immuno-
fl  uorescent staining for Slug (red), YFP (green), and DAPI (blue) in MCF-10A cells transduced with MIY or MIYNotch1IC. Bar, 50     m. (D) qPCR for expression 
of Slug and E-cadherin in MCF-10A cell lines (MIY, MIYNotch1IC, or MIYSlug) transiently transfected with siRandom or siSlug. Data from two independent 
experiments are shown and are expressed as the relative gene expression level with MIY control as the comparator. n.d., not detectable.   JEM VOL. 204, November 26, 2007 
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each of the labeled oligonucleotides was competed away with 
unlabeled wild-type, but not mutated, double-stranded oligo-
nucleotide (  Fig. 2, A and B  ). In addition, lentiviral-delivered 
short hairpin RNAs (shRNAs) targeting two distinct sites of 
CSL (  Fig. 2 C  ) also prevented the gel shift, indicating that these 
sites in the Slug promoter bind endogenous CSL and, thus, 
confi  rming that Slug is a direct target of Notch/CSL. These 
results, combined with our data demonstrating the ability of Slug 
alone (independent of Notch1IC) to induce a spindle-shaped 
morphology and down-regulate E-cadherin expression in nor-
mal breast epithelial cells (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20071082/DC1), identify Slug as a 
key player in the mechanism of Notch-induced EMT. 
  Jagged1/Notch1 correlates with Slug expression in human 
breast cancers 
  To determine whether Jagged1-triggered Notch activation 
could induce Slug expression, Jagged1-expressing mouse en-
dothelial cells (from the SVEC 4-10 cell line) were co-cultured 
human breast cancer xenografts, inhibition of ligand-induced 
Notch signaling inhibits growth of the primary tumor and 
distant metastases, which correlates with reduced Slug expres-
sion and reexpression of E-cadherin. E-cadherin reexpression, 
either through Notch inhibition or enforced expression, is 
associated with relocalization of     -catenin from the nucleus 
to the plasma membrane and reversal of     -catenin activation 
in xenografted breast tumors. Our fi  ndings suggest a critical 
role for induction of EMT and inhibition of anoikis in pro-
moting an aggressive phenotype in tumors exhibiting ligand-
induced Notch signaling. 
    RESULTS   
  Notch activation inhibits E-cadherin expression in human 
breast epithelial cells through the induction of Slug 
  Down-regulation of E-cadherin is one of the best markers of 
EMT in human breast cancer (  12  ). To determine whether 
Notch activation induces EMT in human breast epithelial 
cells as manifested by repression of E-cadherin, the E-cadherin  – 
positive normal human breast epithelial cell line MCF-10A 
was transduced with a retroviral vector (MIY) linking yellow 
fl  uorescent protein (YFP) to activated Notch1 (Notch1IC) 
or activated Notch4 (Notch4IC). Hence, cells that express 
Notch1IC or Notch4IC also express YFP. Expression of either 
Notch1IC or Notch4IC caused this normal breast epithelial 
cell line to down-regulate E-cadherin, dissociate cell  –  cell con-
tacts, and acquire a spindle-shaped morphology, consistent 
with mesenchymal transformation (Fig. S1, A  –  C, available 
at http://www.jem.org/cgi/content/full/jem.20071082/DC1). 
A similar ability of activated Notch to down-regulate E-cad-
herin was demonstrated in primary human breast epithelial 
cells (  Fig. 1 A  ).   
  To identify a potential mechanism of Notch-mediated 
E-cadherin silencing, expression of three known E-cadherin 
repressors that initiate EMT in breast cancer  —  Slug, Snail, and 
Twist1 (  16  )  —  was assessed in a normal breast epithelial cell 
line by quantitative RT-PCR (qPCR). In contrast to what 
has been reported in endothelial cells (  13  ), Snail mRNA 
expression was not detected in either Notch1IC-expressing 
or control cells. Twist1 mRNA levels did not diff  er between 
control and Notch1IC-expressing cells (  Fig. 1 B  ). Slug mRNA 
expression, however, was signifi  cantly increased in Notch1IC 
cells, which was associated with a decrease in E-cadherin 
mRNA expression (  Fig. 1 B  ). Notch1IC-induced expression 
of Slug protein was confi  rmed by immunofl  uorescence micros-
copy (  Fig. 1 C  ). Knockdown of Slug, achieved by delivering 
small interfering RNA (siRNA) targeting Slug, into cells trans-
duced with either Notch1IC or Slug was suffi   cient to restore 
E-cadherin expression (  Fig. 1 D  ). 
  To determine whether Slug is a direct target of Notch/
CSL, we examined the human Slug promoter and identifi  ed 
two potential CSL-binding consensus motifs (  −  846 to   −  853 
and   −  1686 to   −  1679 relative to the transcriptional start site). 
EMSAs using double-stranded oligonucleotides spanning these 
sites showed a clear gel shift of MDA-MB-231 human breast 
carcinoma nuclear lysates (  Fig. 2, A and B  ).   The binding of 
  Figure 2.     Slug is a direct target of Notch signaling. EMSA of 
  nuclear lysates from MDA-MB-231 human breast cancer cells transduced 
with nonspecifi  c shRNA (shRand) or two different shRNAs targeting CSL 
(shCSL1 and shCSL2). CSL consensus binding sites in the human Slug 
promoter (A,   −  846 to   −  853 [TATGGGAA]; and B,   −  1686 to   −  1679 
[TGTGGGAA]) relative to the transcriptional start site were used as the   32 P-
labeled probe, and either nonradioactive wild-type or mutated (mt) oligo-
nucleotides were used as competitors in 50-fold excess. The CSL  –  DNA 
protein complex and the free DNA probe are identifi  ed by arrows. 
(C) shRNA-mediated knockdown of CSL in MDA-MB-231 cell lines was 
verifi  ed by RT-PCR analysis.     2938 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
or the Notch ligand Jagged1 (  7  ). To examine whether increased 
Slug expression would be found in breast cancers showing 
increased Jagged1 or Notch1 expression, we accessed a com-
pendium of 132 independent gene expression datasets repre-
senting   >  10,000 microarray experiments in the Oncomine 
database (  17  ). Expression of both Jagged1 and Notch1 corre-
lated positively with Slug in two independent breast cancer 
datasets (  Fig. 3, B and C  ). Of signifi  cance, a positive correlation 
between the expression of Jagged1 and Slug, but not Snail, 
was observed in numerous cancers other than the breast, which 
was consistent with our fi  nding that Jagged1 is capable of 
inducing Slug but not Snail (  Fig. 3 D  ). 
with normal parental MCF-10A cells, and qPCR using human-
specifi  c primers was used to measure Slug expression in the 
human breast epithelial cells. Jagged1-induced Notch activa-
tion, as demonstrated by induction of the target gene   HEY1   
(Fig. S2 E), resulted in increased levels of Slug mRNA levels 
with a concomitant decrease in E-cadherin mRNA expres-
sion in these normal breast epithelial cells (  Fig. 3 A  ).   These 
fi  ndings show that Jagged1 expression can activate Notch sig-
naling in a juxtacrine manner to induce Slug expression and 
mesenchymal transformation of breast epithelial cells. 
  Poor prognosis for breast cancer patients has been shown 
to correlate with elevated levels of expression of either Slug (  16  ) 
  Figure 3.     Jagged1 and Slug expression are correlated in human breast epithelial cells and in primary human breast cancer. (A) qPCR for ex-
pression of Slug and E-cadherin in MCF-10A parental cells co-cultured with mouse endothelial cells transduced with MIY vector control (  −  Jagged1) or 
MIYJagged1 (+Jagged1). Human-specifi  c primers were used to avoid amplifi  cation of mouse transcripts and limit analysis to MCF-10A cells. Data are 
expressed as the relative gene expression level, with the empty vector control co-culture (  −  Jagged1) as the comparator, and are from three independent 
experiments (mean + SEM). Slug: *, P   ≤   0.05; E-cadherin: *, P   <   0.0001. (B  –  D) Expression correlations in primary human cancers. Pearson correlation coeffi  -
cients were obtained from microarray datasets deposited in the Oncomine database. For each dataset, individual correlations between two genes of 
interest (as well as all possible correlations in cases where replicate probes were present in the microarray) are represented by open circles. Bars represent 
the mean Pearson correlation coeffi  cient. The numbers of normal and cancer specimens included in the correlation analysis for each dataset are indicated. 
(B) Expression correlations between Jagged1 and Slug in primary human breast cancer. Jagged1 expression correlations with Snail are also shown. *, 
P   <   0.01; **, P   <   0.001. (C) Expression correlations between Notch1 and Slug in primary human breast cancer. Notch1 expression correlations with Snail 
are also shown. *, P   <   0.01; **, P   <   0.001. (D) Expression correlations between Jagged1 and Slug in various primary human cancers. Where available, 
expression correlations between Jagged1 and Snail are also shown. *, P   ≤   0.05; **, P   <   0.01; ***, P   <   0.001. n.d., not determined.   JEM VOL. 204, November 26, 2007 
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  Although these fi  ndings suggest that repression of E-cad-
herin is mediated by Slug and not HES/HEY, HEY genes 
may represent surrogate markers of activation of the Jagged1  – 
Notch  –  Slug signaling axis in human breast cancer. Examination 
of two independent breast cancer microarray datasets confi  rmed 
positive expression correlations between Jagged1 and HEY1, 
HEY2, and HEYL, respectively (  Fig. 4 C  ). Moreover, the 
expression of HEY1, HEY2, and HEYL were all positively 
correlated with the expression of Slug but not Snail (  Fig. 4 D  ). 
Thus, the HEY genes may be potential markers of human breast 
cancers that exhibit Notch activation and may, therefore, 
classify a subset of breast cancer patients that would benefi  t 
from therapeutics specifi  cally designed to target the Jagged1  –
  Notch  –  Slug pathway. 
  Inhibition of ligand-induced Notch activation blocks growth 
and metastasis of breast tumors in vivo 
  To determine whether blockade of Notch ligand  –  receptor 
interaction would reverse Slug-induced EMT and inhibit breast 
  HEY genes are potential markers of human breast cancers 
that exhibit activation of the Jagged1  –  Notch  –  Slug 
signaling axis 
  In response to Notch activation, transcriptional repressors of 
the HES and HEY families of basic helix-loop-helix proteins 
are induced (  18  ). Cell type and context determine which 
members are induced (  18  ). qPCR was used to analyze whether 
HES1 and HEY1/2/L were up-regulated in response to Notch 
activation in breast epithelial cells. Although HES1 levels did 
not diff  er between vector control and Notch1IC cells, all three 
HEY genes were absent in control cells and up-regulated in the 
presence of Notch1IC (  Fig. 4 A  ).   
  Because HEY proteins, similar to Slug, silence gene ex-
pression by binding to E-boxes in target gene promoters 
(  18  ), we determined whether enforced expression of any 
one of the HEY proteins was sufficient to down-regulate 
E-cadherin. In contrast to Slug (Fig. S2, B-E), none of the three 
HEY proteins altered E-cadherin transcript levels in these 
cells (  Fig. 4 B  ). 
  Figure 4.     HEY genes are potential markers of human breast cancers that exhibit activation of the Jagged1  –  Notch  –  Slug signaling axis. 
(A) qPCR for Notch target genes (HES1, HEY1, HEY2, and HEYL) in MCF-10A MIY and MIYNotch1IC cell lines. Data shown are the mean threshold cycle num-
ber (C  T  ) + SEM from three independent experiments. n.d., not detectable. (B) qPCR for gene expression in MCF-10A cells transduced with MIY, MIYHEY1, 
MIYHEY2, or MIYHEYL. Data show relative gene expression level or threshold cycle number (C  T  ). n.d., not detectable. (C and D) Expression correlations in 
primary human breast cancers. Pearson correlation coeffi  cients were obtained from microarray datasets deposited in the Oncomine database. For each 
dataset, correlations between two genes of interest (as well as all possible correlations in the event of replicate genes in the microarray) are represented 
by open circles. Bars represent the mean Pearson correlation coeffi  cient. The number of normal and cancer specimens included in the correlation analysis 
for each dataset are indicated. n.d., not determined. (C) Expression correlations between Jagged1 and each of the HEY target genes in primary human 
breast cancer. *, P   ≤   0.05; **, P   <   0.001. (D) Expression correlations between each of the HEY target genes and Slug in primary human breast cancer. Where 
available, expression correlations between each of the HEY target genes and Snail are also shown. *, P   <   0.01; **, P   <   0.001. (E) Semiquantitative RT-PCR 
for Notch target genes in MDA-MB-231 MIG and MIGXNotch4HA tumor xenografts. Data are expressed as the relative gene expression level with MIG 
control tumor as the comparator (mean + SEM). *, P   ≤   0.05. n.d.     2940 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
content/full/jem.20071082/DC1). These fi  ndings show that 
inhibition of ligand-induced Notch signaling in breast tumor 
cells can inhibit tumor growth and metastasis. 
  Inhibition of ligand-induced Notch signaling restores 
E-cadherin expression and inactivates     -catenin in breast 
tumors in vivo 
  Having demonstrated an antitumor eff  ect of XNotch4 on 
breast tumor growth in vivo, we sought to determine whether 
inhibition of Notch signaling would reinduce expression of 
E-cadherin in the tumor cells. Lysates from XNotch4 tumor 
xenografts exhibited E-cadherin protein expression in contrast 
to tumors lacking XNotch4, which remained E-cadherin neg-
ative (  Fig. 5 C  ). Because the antibody used recognizes both 
human and mouse E-cadherin, RT-PCR was performed with 
human E-cadherin  –  specifi  c primers to confi  rm E-cadherin re-
expression in the XNotch4 tumor cells (  Fig. 5 D  ). Functional 
reexpression of E-cadherin at the plasma membrane of the 
xenografted tumor cells in response to Notch inhibition was 
demonstrated by immunofl  uorescent microscopy (  Fig. 5 E  ). 
      -Catenin contributes to breast tumorigenesis by regulat-
ing the expression of genes involved in proliferation, inva-
sion, and EMT ( 27  ). When    -catenin is bound to E-cadherin, 
signaling-competent nuclear     -catenin levels diminish, and 
cell proliferation and invasion are suppressed (  28  ). To deter-
mine whether surface E-cadherin reexpression in XNotch4 
tumors would aff  ect     -catenin activity, we immunoblotted 
tumor cell lysates with an antibody specifi  c for active     -catenin 
and found signifi  cantly reduced     -catenin activity in tumors 
where Notch activation was blocked (  Fig. 5 C  ). Consistent 
with this fi  nding,     -catenin relocated from the nucleus to 
the plasma membrane in tumors where Notch was inhibited 
(  Fig. 5, E and F  ). 
  To verify that activated Notch is able to activate     -catenin 
function, we examined expression of the     -catenin target 
genes in Notch-activated MCF-10A cells by qPCR. Interest-
ingly, Notch activation induced Axin2 and APCDD1 but not 
Lef1 (Fig. S5 A, available at http://www.jem.org/cgi/content/
full/jem.20071082/DC1). In parental MCF-10A cells, Wnt3a 
stimulation also induced Axin2, but not Lef1 (Fig. S5 B), sug-
gesting that the active     -catenin levels correlate with tran-
scriptional activation. However, conditioned medium from 
Notch-activated cells did not induce Axin2 (Fig. S5 C), sug-
gesting that the observed     -catenin activation is independent 
of a secreted factor. Further, inhibition of Wnt activation by 
Dkk1 did not block activation of the     -catenin target Axin2 
in Notch-activated cells, whereas Dkk1 did block Wnt3a-
induced Axin2 (Fig. S5, C and D), thereby confi  rming Wnt-
independent activation of     -catenin by Notch. 
  To determine whether enforced expression of E-cadherin 
was suffi   cient to reproduce the phenotype induced by blockade 
of Notch signaling, we transduced MDA-MB-231 cells with 
E-cadherin complementary DNA (cDNA) and implanted 
vector- or E-cadherin –  expressing cells onto the backs of immuno -
defi  cient mice. Enforced expression of E-cadherin (independent 
of Notch inhibition) was suffi   cient to inhibit tumor growth and 
tumor invasion and metastasis, we used the Slug-positive/
E-cadherin  –  negative MDA-MB-231 human breast carcinoma 
cell line. MDA-MB-231 cells possess a wild-type E-cadherin 
gene and, thus, exhibit reversible E-cadherin silencing (  19  ), 
and they also express Notch4 (  20  ). We confi  rmed Notch4 
expression and also found that MDA-MB-231 cells expressed 
multiple other Notch receptors and ligands, thus providing 
these cells with the potential to activate Notch signaling 
through juxtacrine/autocrine ligand  –  receptor interactions 
(Fig. S3 A, available at http://www.jem.org/cgi/content/
full/jem.20071082/DC1). 
  To target the Notch pathway in vivo, we chose to use 
a soluble Notch receptor, which has been shown to block 
ligand-induced Notch signaling (  21  ), rather than     -secretase 
inhibitors that can directly increase the expression of E-cad-
herin by preventing its proteolysis (  22  ). MDA-MB-231 cells 
were retrovirally transduced with the soluble ectodomain of 
human Notch4 (XNotch4) to block ligand-induced Notch 
activation. Secretion of the soluble protein was confi  rmed by 
immunoblotting the concentrated medium in which the cells 
were cultured (Fig. S3 B). The ability of XNotch4 to in-
hibit tumor growth in vivo was tested in a xenograft model 
by implanting XNotch4-secreting MDA-MB-231 cells sub-
cutaneously into immunodefi  cient mice. Expression of XNotch4 
protein in the xenografts was confi  rmed by immunohisto-
chemistry (Fig. S3 C). 
  We assessed the mRNA levels of HEY genes in this 
model to determine whether any of the HEY genes were 
down-regulated and to confi  rm inhibition of the Notch 
pathway. Interestingly, of the three Notch target genes as-
sessed, only HEYL exhibited a decrease in mRNA expression 
similar to Slug in XNotch4 tumors (  Fig. 4 E and   see   Fig. 6 A  ). 
The reason for this is not clear, but given that some HEY genes 
are also downstream targets of other signaling pathways, 
such as TGF-     (  23  ), it is possible that in our model HEYL 
is up-regulated solely by the Notch pathway, whereas other 
factors may also be up-regulating HEY1/2. Hence, inhibition 
of Notch would only block HEYL expression, but would not 
abrogate expression of HEY1/2. 
  Tumor growth was signifi  cantly inhibited using XNotch4 
to inhibit ligand-induced Notch signaling (  Fig. 5 A  ).   Inhibi-
tion of tumor growth was also achieved by enforced expression 
of soluble extracellular Notch1 or dominant-negative CSL, 
confi  rming that direct inhibition of Notch signaling within 
the tumor cells attenuates growth in MDA-MB-231 tumors 
(unpublished data). In addition to inhibiting the growth of the 
primary implant, attenuation of Notch signaling also reduced 
the number and size of metastases, as would be expected with 
inhibition of EMT (  Fig. 5 B  ). 
  Because aberrant Notch signaling results in disrupted 
blood vessel development ( 24  –  26  ), we determined whether 
attenuated tumor growth could be explained by an anti-
angiogenic eff  ect of XNotch4. We did not observe diff  erences in 
vascular density in the implanted tumors, suggesting that angio-
genesis inhibition is not the mechanism of tumor suppression 
in this model (Fig. S4, available at http://www.jem.org/cgi/JEM VOL. 204, November 26, 2007 
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  Figure 5.     Inhibition of ligand-induced Notch activation blocks breast tumor growth and metastasis, restores E-cadherin expression, and 
inactivates     -catenin in vivo. (A) Tumor growth curves for MDA-MB-231 cells transduced with MIG or MIGXNotch4HA grown as xenografts on the 
dorsa of immunodefi  cient mice. Data are presented as the mean   ±   SEM of the tumor volumes. *, P   <   0.01. (B) Quantitation of metastases in MDA-MB-231 
MIG and MIGXNotch4HA tumor-bearing mice. Data shown represent the mean number of metastases per mouse + SEM and the mean weight of each 
metastatic nodule + SEM. *, P   ≤   0.05. (C) Immunoblots for expression of XNotch4HA, E-cadherin, active     -catenin, and     -tubulin in MDA-MB-231 MIG 
and MIGXNotch4HA tumors. Protein expression was quantitated by densitometry and normalized to     -tubulin. Data shown represent mean + SEM. *, P   ≤   
0.05. (D) RT-PCR for expression of human E-cadherin in MDA-MB-231 MIG and MIGXNotch4HA tumors. Human-specifi  c primers were used to avoid am-
plification of mouse E-cadherin. (E) Immunofluorescent staining for E-cadherin (red),     -catenin (red), and DAPI (blue) in MDA-MB-231 MIG and 
MIGXNotch4HA tumors. Bar, 15     m. (F) Quantitation of the proportion of cells exhibiting nuclear     -catenin staining in MDA-MB-231 MIG and 
MIGXNotch4HA tumors. Data shown represent mean + SEM. *, P   ≤   0.05. (G) Tumor growth curves for MDA-MB-231 cells transduced with MIY or MIYE-
cadherin grown as xenografts on the dorsa of immunodeficient mice. Data are presented as the mean   ±   SEM of the tumor volumes. *, P   <   0.001. 
(H) Quantitation of metastases in MDA-MB-231 MIY and MIYE-cadherin tumor-bearing mice. Data shown represent the mean number of metastases per 
mouse + SEM and the mean weight of each metastatic nodule + SEM. *, P   <   0.001. (I) Immunoblots for expression of E-cadherin and     -tubulin in MDA-
MB-231 MIY and MIYE-cadherin tumors. (J) Immunofl  uorescent staining for E-cadherin (red),     -catenin (red), and DAPI (blue) in MDA-MB-231 MIY and 
MIYE-cadherin tumors. Bar, 15    m.   2942 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
  Figure 6.     Restoration of E-cadherin expression by Notch inhibition is associated with Slug down-regulation and attenuation of E-cadherin 
promoter methylation. (A) qPCR for expression of Slug, Snail, and Twist1 in MDA-MB-231 MIG and MIGXNotch4HA tumors. Data are expressed as the 
relative gene expression level with MIG control tumors as the comparator (mean + SEM). *, P   ≤   0.01. (B) Immunofl  uorescent staining for Slug (red), GFP 
(green), and DAPI (blue) in MDA-MB-231 MIG and MIGXNotch4HA tumor xenografts. Yellow represents the overlap of GFP and Slug immunostaining. JEM VOL. 204, November 26, 2007 
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Treatment of NotchIC- or Slug-expressing breast epithelial 
cells with the HDAC inhibitors trichostatin A (TSA) and 
sodium butyrate (NaBu), either alone or together, was suf-
fi  cient to reverse the down-regulation of E-cadherin ex-
pression by Notch1IC or Slug (  Fig. 6, F and G  ). A current 
molecular model for transcriptional gene silencing suggests 
that histone deacetylation is a primary event involved in the 
initiation of chromatin compaction, and that DNA methyla-
tion functions subsequent to histone deacetylation to estab-
lish a permanent state of gene inactivation (  30  ). NotchIC- or 
Slug-expressing cells were thus treated with the DNA methyl-
transferase inhibitor 5-azacytidine (5AZA), which also elic-
ited reinduction of E-cadherin expression. However, 5AZA 
and TSA/NaBu together did not produce an additive eff  ect 
on E-cadherin reexpression, suggesting that DNA methylation 
may occur secondary to histone deacetylation, as previously 
suggested (  30  ). 
  The E-cadherin promoter contains numerous cytosine-
phosphate-guanine (CpG) sites, which result in E-cadherin 
silencing when methylated on the corresponding cytosine 
residue (  31  ). Given that DNA methylation has been reported 
to be dominant over histone deacetylation in mediating gene 
silencing (  32  ), as well as our data suggesting that methyla-
tion may occur as a later step in silencing the E-cadherin 
promoter, we sought to determine whether reduced Slug 
expression and reexpression of E-cadherin in our breast tumor 
xenografts correlated with reduced DNA methylation at the 
E-cadherin promoter. Using two independent methods, 
methylation-specifi  c PCR (MSP) and genomic bisulfi  te se-
quencing, E-cadherin promoter methylation in XNotch4 
tumors was found to be reduced compared with control 
tumors (  Fig. 6, H and I  ). Because XNotch4 tumors did not 
display generalized hypomethylation of the genome (Fig. S6, 
A and B, available at http://www.jem.org/cgi/content/full/
jem.20071082/DC1), Notch inhibition likely results in de-
methylation at specifi  c promoters regulated by Notch/Slug. 
These results suggest that inhibition of Notch signaling re-
induces E-cadherin by repressing Slug and reversing E-cadherin 
promoter methylation. 
metastasis with concomitant relocalization of     -catenin to the 
plasma membrane (  Fig. 5, G  –  J  ). These data suggest that in-
hibition of ligand-induced Notch activation is tumor sup-
pressive, in part because of reinduction of surface E-cadherin 
expression. This in turn retains     -catenin at the plasma mem-
brane, thereby attenuating     -catenin nuclear activity and in-
hibiting tumor growth and metastasis. 
  Restoration of E-cadherin expression by Notch inhibition 
is caused by Slug down-regulation and attenuation 
of E-cadherin promoter methylation 
  To determine whether inhibition of ligand-induced Notch 
signaling restored E-cadherin expression secondary to repres-
sion of Slug, expression of the genes encoding Slug, Snail, 
and Twist1 was assessed by qPCR in the breast tumor xeno-
grafts. Although transcript levels of Snail and Twist1 did not 
diff  er between control and XNotch4 tumors, Slug expression 
was signifi  cantly reduced when Notch signaling was inhibited 
(  Fig. 6 A  ).   XNotch4 also blocked expression of Slug protein, 
because Slug was only present in areas of the tumor where 
XNotch4 was absent, as determined by immunofl  uorescent 
staining of breast tumor xenografts (  Fig. 6 B  ). 
  To directly demonstrate that Jagged1 could induce Slug 
in breast tumor cells, MDA-MB-231 parental cells were co-
  cultured with mouse stromal cells transduced with either 
Jagged1 or empty vector, and human Slug transcript levels 
were quantitated by RT-PCR using human-specifi  c Slug 
primers. In response to Jagged1-induced Notch signaling, 
Slug transcripts in MDA-MB-231 cells were increased approxi-
mately fi  vefold (  Fig. 6 C  ). To prove that Slug was responsible 
for E-cadherin repression in these cells, Slug was targeted using 
lentiviral-delivered shRNA in breast tumor cells. Knockdown 
of Slug was confi  rmed by qPCR and immunoblotting, and 
was found to be suffi   cient to restore expression of E-cadherin 
(  Fig. 6, D and E  ). 
  Because Slug recruits histone deacetylase (HDAC) com-
plexes to mediate transcriptional silencing (  29  ), we deter-
mined whether HDAC activity was required for the ability of 
Notch-induced Slug to down-regulate E-cadherin expression. 
Bar, 100     m. (C) qPCR for gene expression in MDA-MB-231 parental cells co-cultured with mouse endothelial cells transduced with MIY vector control 
(  −  Jagged1) or MIYJagged1 (+Jagged1). Human-specifi  c primers were used to assay Slug specifi  cally in MDA-MB-231 cells and avoid amplifi  cation of mouse 
transcripts. Data are expressed as the relative gene expression level, with the empty vector control co-culture (  −  Jagged1) as the comparator, and are from 
three independent experiments (mean + SEM). *, P   ≤   0.05. (D) qPCR for expression of Slug and E-cadherin in MDA-MB-231 cells transduced with shRan-
dom or shSlug. Data from two independent experiments are shown and are expressed as the relative gene expression level with shRandom control as the 
comparator. (E) Immunoblot for expression of E-cadherin, Slug, and     -tubulin in MDA-MB-231 cells transduced with shRandom or shSlug. (F) Quantita-
tion of the proportion of MCF-10A cells transduced with MIY or MIYNotch1IC that are positive for both YFP and E-cadherin. Cells were treated with TSA 
(100/500/1000 nM), NaBu (2/5/10 mM), or 5AZA (1/5/10     M) alone or in combination, and E-cadherin expression was assessed 3 d after treatment by 
immunofl  uorescent microscopy. Data shown represent mean + SEM of at least three independent experiments. *, P   ≤   0.05. (G) Quantitation of the propor-
tion of MCF-10A cells transduced with MIY or MIYSlug that are positive for both YFP and E-cadherin. Cells were treated with TSA (100/500/1000 nM), 
NaBu (2/5/10 mM), or 5AZA (1/5/10     M) alone or in combination. Data shown represent mean + SEM of at least three independent experiments. *, P   ≤   
0.05. (H) MSP to assess methylation status of the E-cadherin promoter in MDA-MB-231 tumors. Primers specifi  c for methylated (M) or unmethylated (U) 
E-cadherin promoter were used. Amplifi  ed M and U products were quantitated by densitometry and expressed as the M/U ratio. Data shown represent 
mean + SEM. *, P   <   0.001. (I) Genomic bisulfi  te sequencing to assess methylation status of the E-cadherin promoter in MDA-MB-231 tumors (MIG,   n   =  35 
clones from fi  ve tumors; MIGXNotch4HA,   n   = 22 clones from three tumors). A total of 22 CpG sites within the E-cadherin proximal promoter (  −  104 to 
+118) were analyzed. Data shown represent the percentage of methylation observed at each CpG site.     
 2944 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
  The Notch  –  Slug signaling axis inhibits anoikis of human 
breast cells 
  During cancer progression and dissemination, malignant can-
cer cells enter the circulation or lymphatic system and then 
must survive in the vasculature until they successfully extrav-
asate into a tissue site. Cell death associated with abolished 
matrix-initiated integrin signaling has been termed anoikis. 
For a tumor cell to metastasize to a distant site, it needs to 
overcome anoikis. Activated Notch inhibits apoptosis in 
response to various triggers in diff  erent cell types, but it has 
also been reported to induce apoptosis in other situations (  11, 
33, 34  ). We thus asked whether breast epithelial cells express-
ing Notch1IC or Slug would exhibit a survival advantage 
compared with control cells when maintained under conditions 
that prevented adhesion. For this assay, cells were placed in 
suspension cultures, rather than soft agar (  11  ), to mimic transit 
through the bloodstream. Both NotchIC- and Slug-expressing 
breast epithelial cells exhibited protection against anoikis 
compared with control cells (  Fig. 7 A  ).   Conversely, breast tumor 
xenografts in which Notch signaling was inhibited showed 
reduced Slug expression (  Fig. 6, A and B  ), with a concomi-
tant increase in cell death as measured by activated Caspase 3 
levels (  Fig. 7 B  ). 
    DISCUSSION   
  Although mouse models have indicated that mammary-spe-
cifi  c overexpression of a truncated constitutively active Notch 
can result in breast tumors, human data suggest that both 
Notch ligands and receptors are up-regulated in a proportion 
of breast cancers and that this expression is correlated with 
poor outcome. The implication is that juxtacrine or auto-
crine Notch activation, rather than activating Notch muta-
tions, may be responsible for an aggressive tumor phenotype. 
This is in marked contrast to T cell acute lymphoblastic leuke-
mia, where more than half of the cases have activating muta-
tions of Notch1 (  35  ). In this paper, we have shown that Jagged1 
activation of Notch up-regulates the transcriptional repressor 
Slug to promote carcinogenesis by two cellular mechanisms: 
(a) by facilitating cancer cell metastasis through initiation of 
EMT, and (b) by enhancing cell survival in the absence of cell 
matrix adhesion. Importantly, we have demonstrated that, in 
human breast cancers, expression of Jagged1 and Notch1 cor-
relates positively with Slug expression. 
  In breast cancer patients, increased expression of either 
Jagged1 or Notch1 is predictive of poor overall survival (  7  ). 
If both Jagged1 and Notch1 are increased, there is a further 
substantial reduction in overall survival (  7  ). Our data provide 
an explanation for the reported dose-dependent relationship of 
Jagged1 expression and negative outcome in breast cancer (  7  ), 
suggesting that juxtacrine or autocrine Jagged1  –  Notch inter-
actions induce Slug, which initiates EMT and inhibits anoikis, 
thereby promoting tumor invasion and metastasis. Interest-
ingly, Jagged1 expression has also been associated with prostate 
cancer metastasis and recurrence (  36  ), and our demonstration 
of positive correlations between Jagged1 and Slug expression 
in a wide variety of tumors raises the possibility that our fi  nd-
ings may be generalized to other tumors in which Notch is 
activated by ligand. 
  Expression of the Notch target gene   HEYL   has previously 
been reported to be absent in the normal breast epithelium 
but present in the tumor cell compartment of invasive breast 
cancers (  37  ). These fi  ndings fi  t with our results, which show 
that   HEYL   mRNA is undetectable in control breast epithe-
lial cells but is up-regulated in cells exhibiting activation 
of the Notch  –  Slug signaling axis. Importantly, our analysis 
of primary human breast cancers has identifi  ed HEY genes, 
in particular   HEYL  , as potential markers of human breast 
cancers that exhibit activation of the Jagged1  –  Notch  –  Slug 
signaling axis. 
  The Snail gene has previously been reported to be a di-
rect target gene of Notch in endothelial cells (  13  ). However, 
our data suggest that this is not the case in epithelial cells, be-
cause we did not observe a positive correlation between acti-
vated Notch signaling and Snail induction. Rather, we observed 
a positive correlation between Notch activation and Slug ex-
pression both in human breast epithelial cells in vitro and in 
primary human breast cancers. Hence, our fi  ndings indicate 
that Slug, but not Snail, is a downstream target gene of Notch 
in epithelial and other tumors. Interestingly, increased levels of 
  Figure 7.     The Notch  –  Slug signaling axis inhibits anoikis of 
human breast cells. (A) Anoikis assay to assess cell death in MCF-10A 
cell lines (MIY, MIYNotch1IC, and MIYSlug). The fraction of hypodiploid 
cells was determined by fl  ow cytometry, and the data representing the 
mean + SEM of three independent experiments are expressed as the fold 
change in hypodiploid cells relative to MIY control. MIYNotch1IC: *, P   <   
0.01; MIYSlug: *, P   ≤   0.05. (B) Immunohistochemical staining for activated 
caspase 3 in implanted MDA-MB-231 MIG and MIGXNotch4HA tumors. 
Data representing the mean + SEM are shown as the proportion of the 
activated caspase 3  –  stained area compared with the total tumor area. 
*, P = 0.012. Bar, 25    m.   JEM VOL. 204, November 26, 2007 
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play a role in maintaining the tumor stem cell, as well as in 
permitting these cells to survive the metastatic process. 
  Tumor cell metastasis is the primary cause of mortality in 
a vast majority of cancer patients. As such, there is a compel-
ling need to elucidate the mechanisms of tumor cell metastasis 
and to develop rationally designed therapeutics to specifi  cally 
target the metastatic process. Our fi  ndings highlight the po-
tential use of inhibitors of ligand-induced Notch signaling as 
viable and eff  ective agents to block EMT and tumor metasta-
sis in the treatment of human cancers that exhibit activation 
of the Jagged1  –  Notch  –  Slug signaling axis. By specifi  cally tar-
geting ligand-induced activation, there is the potential of re-
ducing the more widespread side eff  ects potentially evoked by 
less-specifi  c therapeutics, such as the     -secretase inhibitors. 
  MATERIALS AND METHODS 
  Cell lines.     The human breast epithelial cell line MCF-10A was cultured in 
a 1:1 mixture of DMEM/F12 (Sigma-Aldrich) supplemented with 5% horse 
serum (Sigma-Aldrich), 2 mM glutamine (Sigma-Aldrich), 20 ng/ml of epi-
dermal growth factor (Sigma-Aldrich), 100 ng/ml cholera toxin (Cedarlane), 
10     g/ml insulin (Sigma-Aldrich), 500 ng/ml hydrocortisone (Sigma-
Aldrich), and 100 U/ml each of penicillin and streptomycin (Invitrogen). 
The human breast carcinoma cell lines MDA-MB-231 and T47D and the 
mouse endothelial cell line SVEC4-10 were cultured in DMEM supple-
mented with 10% heat-inactivated calf serum (HyClone), 2 mM glutamine, 
and 100 U/ml each of penicillin and streptomycin. All cells were maintained 
at 37  °  C in an atmosphere of 5% CO  2  . 
  Isolation of primary human breast epithelial cells.     Normal human 
breast tissue was obtained in accordance with guidelines approved by the 
University of British Columbia from anonymized discarded material from 
normal premenopausal women undergoing reduction mammoplasty sur-
geries. A crude epithelial cell  –  enriched cell suspension was obtained enzy-
matically and cryopreserved. As required, cells were thawed, and single-cell 
suspensions were prepared as previously described (  45  ). Cells were co-
cultured with 1.2   ×   10  6   X-irradiated NIH3T3 mouse fi  broblasts for 1 d in 
Epicult-B medium (StemCell Technologies Inc.) supplemented with 5% FCS. 
Cells were harvested, and epithelial cell adhesion molecule (EpCAM)  –  positive 
breast epithelial cells were magnetically separated using the human EpCAM 
selection cocktail EasySep (StemCell Technologies Inc.). These selected cells 
were cultured in Epicult-B medium at a density of 2   ×   10  5   cells per dish in 
35-mm dishes precoated with Vitrogen (Cohesion Technologies). To precoat 
the dishes, 2  –  3 ml of Vitrogen (67     g/ml in PBS) was used for 1 h at 37  °  C 
and washed with PBS before use. 
  Plasmid constructs and gene transfer.     Retroviral vectors (MIY and 
MIG) containing an internal ribosomal entry site and either YFP (MIY) or 
GFP (MIG) were used to facilitate the sorting of transduced cells. cDNA 
constructs encoding the human Notch1IC, C-terminal hemagglutinin 
(HA)-tagged human Notch4IC, full-length C-terminal Flag-tagged human 
Slug (a gift of E. Fearon, University of Michigan, Ann Arbor, MI), full-
length human Jagged1, full-length human E-cadherin (a gift of B.M. 
Gumbiner, University of Virginia, Charlottesville, VA), and N-terminal myc-
tagged full-length human HEY1/2/L (a gift of D. Srivastava, University of 
California, San Francisco, San Francisco, CA) were subcloned into MIY. The 
cDNA construct encoding the entire extracellular domain of human Notch4 
(XNotch4; amino acids 1  –  1,443) tagged with a C-terminal HA epitope 
was subcloned into MIG. The pLentilox3.7-shRandom and pLentilox3.7-shSlug 
constructs were generated by inserting shRNAs targeting the sequences 
5    -GTTGCTTGCCACGTCCTAGAT-3     (Random) and 5    -GCATTT-
GCAGACAGGTCAAAT-3     (Slug) into pLentilox3.7 (a gift of L. Van Parijs, 
Massachusetts Institute of Technology, Cambridge, MA). Cells were transduced 
Slug, but not Snail, have been associated with tumors from 
patients with metastatic disease or disease recurrence (  16  ). 
  Although it has been reported that Slug has antiapoptotic 
activity in some cell types, the current study is the fi  rst dem-
onstration that Slug can inhibit anoikis. To initiate EMT, re-
pression of E-cadherin permits loss of cell  –  cell cohesion, thereby 
disrupting apical-basal polarity and promoting cell migration. 
However, given that the loss of E-cadherin renders cells sus-
ceptible to anoikis, Slug must independently promote cell 
survival in this context to allow local tumor invasion and distant 
metastases. Thus, our fi  ndings that Notch blockade inhibits 
growth of the primary tumor by triggering apoptosis and re-
duces distant metastases is concordant with this model of Slug-
dependent EMT and cell survival. 
  Both Slug and Notch have been shown to inhibit p53 
function, in part through the inhibition of Puma expression, 
which may be one mechanism of the antianoikis eff  ect (  11, 38  ). 
Notch has also been shown to activate the phosphatidylinositol 
3    -kinase  –  Akt antiapoptotic pathway, but whether there is 
cross talk with Slug remains to be seen (  39, 40  ). The ability of 
Notch to suppress c-Jun N-terminal kinase activation and 
activate phosphatidylinositol 3    -kinase  –  Akt may explain the 
inhibition of p53 by Notch (  11, 33, 39  ). Both Notch and Slug 
have also been shown to induce Bcl-2 (  33, 41  ); thus, there are 
multiple potential anoikis  –  apoptosis pathways that Notch may 
regulate through Slug. 
  It is also possible that Slug-mediated repression of E-cad-
herin, which we have shown results in activation of     -catenin, 
may be responsible for an antianoikis eff  ect. Indeed, even 
modest overexpression of active     -catenin has been shown to 
prevent anoikis (  42  ). Of interest,     -catenin has been reported 
to induce Slug promoter activity (  43  ). Hence, Notch induc-
tion of Slug is potentially enhanced by a feed-forward loop. 
Initially, Notch/CSL would directly induce Slug. Subsequent 
Slug-mediated E-cadherin repression, via interaction with 
E2-boxes in the E-cadherin promoter (  12  ), would then release 
    -catenin from the plasma membrane, which would accu-
mulate in the nucleus and further activate the Slug promoter. 
However, the human Slug promoter also contains several cis 
elements predicted to bind the   HEY  /  HES   family of Notch-
induced transcriptional repressors (unpublished data). Thus, 
these factors may act to attenuate the positive feedback loop 
described. Of note, our data showed that enforced expression 
of E-cadherin mimicked the eff  ects of blocking Notch signal-
ing in vivo, suggesting that a major function of Notch-induced 
Slug in this model may be to repress E-cadherin. 
  Recent evidence has demonstrated that breast cancers may 
be initiated in and propagated by a minority cell population 
that have been designated tumor stem cells (  44  ). Notch signal-
ing appears to play an important role in normal mammary stem 
cell self-renewal (  44  ). Thus, the Notch pathway may be selec-
tively activated in more primitive cancer stem cells. A mouse 
transgenic model of activated Notch4-driven breast cancer in-
dicates that these tumors are highly metastatic (  3  ). Interestingly, 
Slug has been shown to have antiapoptotic activity in hema-
topoietic progenitor cells (  38  ); thus, the Notch  –  Slug axis may 2946 JAGGED  –  NOTCH SIGNALING INDUCES EMT THROUGH SLUG | Leong et al.
annealing temperatures are described in Tables S1 and S2. Entire MSP reactions 
were assessed in 2% TAE-agarose gels containing ethidium bromide. Bands 
corresponding to methylated and unmethylated PCR products were quanti-
tated by densitometry. Data are expressed as a ratio of methylated over un-
methylated PCR products (M/U ratio) and represent the mean ratio + SE from 
fi  ve control tumors and fi  ve XNotch4 tumors. For genomic bisulfi  te sequenc-
ing, bisulfi  te-modifi  ed genomic DNA isolated from tumor tissue was amplifi  ed 
by PCR using primers spanning the E-cadherin proximal promoter. Primer 
sequences and annealing temperatures are described in Tables S1 and S2. PCR 
products were purifi  ed and cloned into the pDrive cloning vector (QIAGEN), 
and individual clones were sequenced. Five control tumors (a total of 35 MIG 
clones) and three XNotch4 tumors (a total of 22 XNotch4 clones) were 
analyzed, and data were expressed as the percentage of methylation per CpG 
site (total number of methylated clones/total number of clones). 
  Immunostaining.     Breast epithelial cells were stained with mouse mono-
clonal antibody to extracellular E-cadherin (Chemicon) or rabbit polyclonal 
antibody to Slug (Santa Cruz Biotechnology, Inc.). 7-    m-thick tumor cryo-
sections were stained with rabbit polyclonal antibody to Slug (Santa Cruz 
Biotechnology, Inc.), mouse monoclonal antibodies to E-cadherin (BD Bio-
sciences) or     -catenin (BD Biosciences), and rabbit monoclonal antibody to 
activated caspase-3 (BD Biosciences). For immunohistochemistry, a biotin-
ylated goat anti  –  rabbit antibody (Vector Laboratories) followed by horseradish 
peroxidase  –  conjugated streptavidin (Vector Laboratories) were used, and 
nuclei were counterstained with hematoxylin. For immunofl  uorescence, the 
fl   uorochrome-conjugated secondary antibodies goat anti  –  rat Alexa Fluor 
594 (Invitrogen) and goat anti  –  mouse Alexa Fluor 594 (Invitrogen) were 
used, and nuclei were counterstained with DAPI (Sigma-Aldrich). Immuno-
fl  uorescence was detected with an imaging microscope (Axioplan II; Carl 
Zeiss, Inc.), and images were captured with a digital camera (1350EX; 
QImaging). To quantify the proportion of cells exhibiting nuclear     -catenin 
staining, at least six random fi  elds at 200  ×   magnifi  cation were analyzed per 
tumor using Northern Eclipse software. Data are presented as the mean per-
centage of nuclear     -catenin staining (total number of nuclear     -catenin  –
  positive cells/total number of cells) + SEM from four control tumors and 
four XNotch4 tumors. To quantify the proportional area of tumors showing 
activated caspase 3, entire tumor sections were analyzed using Northern 
Eclipse software. Data are presented as the mean percentage of the activated 
caspase 3  –  stained area (total area positive for activated caspase 3/total area of 
tumor section) + SEM from 14 control tumors and 12 XNotch4 tumors. 
  siRNA transfection.     MCF-10A MIY and MIYNotch1IC cells were fl  ow 
sorted, and YFP-positive cells were transiently transfected with 100 nM 
siRNA targeting the sequences 5    -GTTGCTTGCCACGTCCTAGAT-3     
(siRandom) or 5    -GCATTTGCAGACAGGTCAAAT-3     (siSlug) using 
DharmaFECT 1 transfection reagent (Dharmacon Inc.). Cells were harvested 
4 d after transfection. 
  Co-culture.     10  6   parental human cells (MCF-10A or MDA-MB-231) were 
co-cultured with 10  6   mouse SVEC4-10 endothelial cells transduced with 
MIY control vector or MIYJagged1 and plated in 100-mm tissue culture 
dishes. Cells were harvested after 3 d of co-culture. qPCR was performed 
with human-specifi  c primers to avoid amplifi  cation of mouse transcripts. 
  Anoikis assay.     MCF-10A cell lines were fl  ow sorted, and YFP-positive 
cells were plated into 60-mm tissue culture plates (8   ×   10  5   cells per plate) 
coated with 1% agarose. After 24 h of incubation at 37  °  C, cells were fi  xed/
permeabilized in 70% ethanol and stained with propidium iodide (Sigma-
Aldrich), and the proportion of cells with hypodiploid DNA content was 
determined by fl  ow cytometry. Data are expressed as the proportion of hy-
podiploid cells relative to MIY control. 
  Tumorigenicity assays.     Female nonobese diabetic/severe combined 
immunodefi  cient mice were obtained from the Animal Resource Centre of 
the British Columbia Cancer Research Centre. For MDA-MB-231 tumor 
with empty vector control or vector containing cDNA inserts, and trans-
duced cells were sorted based on YFP or GFP expression using a cell sorter 
(FACS 440; Becton Dickinson). 
  Immunoblotting.     Cultured cells or tumor tissue were lysed and analyzed 
by SDS-PAGE and immunoblotting with rabbit polyclonal antibody to Slug 
(Santa Cruz Biotechnology, Inc.), or mouse monoclonal antibodies to HA 
(Sigma-Aldrich), E-cadherin (BD Biosciences),     -catenin (BD Biosciences), 
active     -catenin (Millipore), and     -tubulin (Sigma-Aldrich). Protein expression 
was quantitated by densitometry. 
  RNA isolation, RT-PCR, and qPCR.     Total RNA isolation was per-
formed using TRI  zol   reagent (Invitrogen) or an RNeasy kit (QIAGEN), 
according to the manufacturers  ’   recommendations. First-strand cDNA was 
synthesized using Superscript II reverse transcriptase (Invitrogen). After ribo-
nuclease H treatment (Invitrogen), PCR was performed. Control reactions 
omitting reverse transcriptase were performed in each experiment. Primer 
sequences and annealing temperatures are described in Tables S1 and S2 (avail-
able at http://www.jem.org/cgi/content/full/jem.20071082/DC1). For RT-
PCR, entire PCR samples were assessed in 1.5% TAE-agarose gels containing 
ethidium bromide. Control human cDNA was generated from pooled total 
RNA isolated from the following human cells: human mammary epithelial 
cells; vascular smooth muscle cells; cervical cancer cells, SiHa; colon cancer 
cells, WiDr; and kidney epithelial cells, 293T. Control mouse cDNA was 
generated from pooled total RNA isolated from the following mouse cells: 
Lewis lung carcinoma cells; endothelial cells, SVEC4-10; and fi  broblasts, 
NIH3T3. For qPCR, reactions were run on a real-time PCR system (ABI 
Prism 7900; Applied Biosystems). Gene expression was detected with SYBR 
green (Applied Biosystems), and relative gene expression was determined by 
normalizing to GAPDH using the     C  T   method. 
  EMSA.     Nuclear lysates were collected from shRandom, shCSL1, and 
shCSL2 overexpressing MDA-MB-231 cells for the CSL EMSA assays. 
The binding reaction (10 mM TrisHCl, 50 mM NaCl, 1 mM EDTA 
[pH 8], 4% glycerol, 2     g PolydI-dC binding buff  er, and 10     g of nuclear 
protein) was performed by preincubating with either 50-fold excess wild-type 
(Slug 850, [forward] GGGCCCTTTTTCCCATAAAAAAAAAG and [reverse] 
GGGAAAAAGGGTATTTTTTTTTCGGG; Slug 1680, [forward] TGTGT-
GTTTTGTGGGAAATGGAG and [reverse] CTCCATTTCCCACAAAA) or 
mutant (Slug 800, [forward] GGGCCCTTTGCAGCATAAAAAAAAAAG 
and [reverse] GGGAAACGTCGTATTTTTTTTTTCGGG; Slug 1600, 
[forward] TGTGTGTTTTGTGCTGCATGGAG and [reverse] CTC-
CATGCAGCACAAAA) nonradioactive duplex oligos for 15 min on ice, 
and then adding a 150,000-cpm   32  P-labeled double-stranded probe and incu-
bating for 30 min at room temperature. Binding reactions were run on 5% 
Tris-Borate EDTA gels and exposed to a phosphorimager plate for 12  –  16 h. 
  Inhibition of histone acetylation and DNA methylation.     MCF-10A 
cell lines were fl  ow sorted, and YFP-positive cells were plated into fourwell 
chamber slides at 7   ×   10  5   cells per well and allowed to adhere and grow for 48 h. 
Cells were then treated with TSA (100/500/1000 nM), NaBu (2/5/10 mM), 
and/or 5AZA (1/5/10     M) for 72 h. After immunofl  uorescent staining for 
E-cadherin, at least six random fi  elds at 200  ×   magnifi  cation were analyzed 
per well using Northern Eclipse software (Empix Imaging). Data are pre-
sented as the percentage of YFP/E-cadherin double-positive cells + SEM. 
  Methylation assays.     Genomic DNA was isolated from cultured cells or 
tumor tissue using a DNeasy tissue kit (QIAGEN) according to the manu-
facturer  ’  s recommendations. 1     g of genomic DNA was bisulfi  te modifi  ed 
using a CpGenome DNA modifi  cation kit (Chemicon) and eluted in 25     l 
Tris-EDTA buff   er, according to the manufacturer  ’  s recommendations. 
MSP was performed using     120 ng of bisulfi  te-modifi  ed DNA, 400 nM of 
5     and 3     primers, 0.2 mM of 2  ’  -deoxynucleoside 5    -triphosphates (Invitrogen), 
1  ×   PCR buff  er, and 0.625 U of HotStarTaq DNA polymerase (QIAGEN), 
according to the manufacturer  ’  s recommendations. Primer sequences and JEM VOL. 204, November 26, 2007 
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